Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.

Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, Green JE.

PLoS One. 2011 Feb 18;6(2):e16694. doi: 10.1371/journal.pone.0016694.

PMID:
21364753
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

miRNA signature associated with outcome of gastric cancer patients following chemotherapy.

Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE.

BMC Med Genomics. 2011 Nov 23;4:79. doi: 10.1186/1755-8794-4-79.

PMID:
22112324
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.

Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Yamada Y, Arao T, Nishio K, Michalowski A, Green JE.

Pharmacogenomics J. 2012 Apr;12(2):119-27. doi: 10.1038/tpj.2010.87. Epub 2010 Dec 21.

PMID:
21173787
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.

Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R.

Ann Surg Oncol. 2011 Sep;18(9):2688-98. doi: 10.1245/s10434-011-1601-y. Epub 2011 Feb 24.

PMID:
21347786
[PubMed - indexed for MEDLINE]
5.

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.

Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E; V-325 Study Group.

J Clin Oncol. 2007 Aug 1;25(22):3205-9.

PMID:
17664467
[PubMed - indexed for MEDLINE]
6.

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.

Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K.

Br J Cancer. 2005 May 23;92(10):1850-4.

PMID:
15870718
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.

Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J, Vallyathan V, Castranova V, Guo NL.

PLoS One. 2010 Aug 17;5(8):e12222. doi: 10.1371/journal.pone.0012222.

PMID:
20808922
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer.

Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.

Int J Oncol. 2010 Nov;37(5):1219-28.

PMID:
20878069
[PubMed - indexed for MEDLINE]
9.

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.

Bain GH, Collie-Duguid E, Murray GI, Gilbert FJ, Denison A, McKiddie F, Ahearn T, Fleming I, Leeds J, Phull P, Park K, Nanthakumaran S, Grabsch HI, Tan P, Welch A, Schweiger L, Dahle-Smith A, Urquhart G, Finegan M, Petty RD.

Br J Cancer. 2014 Mar 18;110(6):1525-34. doi: 10.1038/bjc.2014.45. Epub 2014 Feb 25.

PMID:
24569475
[PubMed - indexed for MEDLINE]
10.

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.

Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E; V-325 Study Group.

J Clin Oncol. 2007 Aug 1;25(22):3210-6.

PMID:
17664468
[PubMed - indexed for MEDLINE]
11.

Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.

Jhawer M, Coit D, Brennan M, Qin LX, Gonen M, Klimstra D, Tang L, Kelsen DP, Shah MA.

Am J Clin Oncol. 2009 Aug;32(4):356-62. doi: 10.1097/COC.0b013e31818c08e8.

PMID:
19381079
[PubMed - indexed for MEDLINE]
12.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group.

J Clin Oncol. 2006 Nov 1;24(31):4991-7.

PMID:
17075117
[PubMed - indexed for MEDLINE]
14.

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R.

Ann Oncol. 2008 Aug;19(8):1450-7. doi: 10.1093/annonc/mdn166. Epub 2008 Jun 16.

PMID:
18558665
[PubMed - indexed for MEDLINE]
Free Article
15.

Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, Ivanova T, Zhang S, Lee M, Wu J, Ngo A, Manesh S, Tan E, Teh BT, So JB, Goh LK, Boussioutas A, Lim TK, Flotow H, Tan P, Rozen SG.

Gastroenterology. 2013 Sep;145(3):554-65. doi: 10.1053/j.gastro.2013.05.010. Epub 2013 May 14.

PMID:
23684942
[PubMed - indexed for MEDLINE]
16.
18.

Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays.

Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84.

PMID:
14734480
[PubMed - indexed for MEDLINE]
Free Article
19.
20.

Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.

Ryoo BY, Kang YK, Im YH, Kim YJ, Kim BS, Kim TY, Jung SH, Park JH, Baek HJ, Kim YC, Shim YM, Kim CM, Zo JI.

Am J Clin Oncol. 1999 Jun;22(3):253-7.

PMID:
10362331
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk